Jaguar Health Temettü

Temettü kriter kontrolleri 0/6

Jaguar Health does not have a record of paying a dividend.

Anahtar bilgiler

n/a

Temettü verimi

-388.1%

Geri Alım Getirisi

Toplam Hissedar Getirisi-388.1%
Gelecekteki Temettü Verimin/a
Temettü Büyümesin/a
Bir sonraki temettü ödeme tarihin/a
Eski temettü tarihin/a
Hisse başına temettün/a
Ödeme oranın/a

Son temettü güncellemeleri

Güncelleme yok

Recent updates

Jaguar Health, Inc. (NASDAQ:JAGX) Stock's 55% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Jul 24
Jaguar Health, Inc. (NASDAQ:JAGX) Stock's 55% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 49%

May 24
Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 49%

Jaguar Health, Inc. (NASDAQ:JAGX) Shares Fly 55% But Investors Aren't Buying For Growth

Mar 29
Jaguar Health, Inc. (NASDAQ:JAGX) Shares Fly 55% But Investors Aren't Buying For Growth

Jaguar Health, Inc. (NASDAQ:JAGX) Not Doing Enough For Some Investors As Its Shares Slump 39%

Jan 22
Jaguar Health, Inc. (NASDAQ:JAGX) Not Doing Enough For Some Investors As Its Shares Slump 39%

Positive Sentiment Still Eludes Jaguar Health, Inc. (NASDAQ:JAGX) Following 32% Share Price Slump

Jun 10
Positive Sentiment Still Eludes Jaguar Health, Inc. (NASDAQ:JAGX) Following 32% Share Price Slump

Jaguar Health (NASDAQ:JAGX) Is Carrying A Fair Bit Of Debt

Jan 23
Jaguar Health (NASDAQ:JAGX) Is Carrying A Fair Bit Of Debt

Jaguar Health rises 19% on orphan drug tag for congenital diarrheal disorder treatment

Oct 17

Jaguar Health sells crofelemer and lechlemer royalty rights for $4M upfront

Aug 25

Jaguar Health gets 180-day grace period to regain compliance with Nasdaq's listing rule

Aug 19

Jaguar Health rises on U.S. patent for treating chemotherapy-induced diarrhea

Aug 09

Jaguar stock rises on license deal with SynWorld for Canalevia in China

Jun 29

Jaguar Health CEO Lisa Conte - From Rainforest To Laboratory

Mar 07

Jaguar Health shares jumps 13% after pricing $15M direct offering

Jan 13

Jaguar Health plans for conditional marketing application in Europe for Crofelemer, initially for Long-Hauler COVID-19 patients

Jan 11

Jaguar Health leaps higher in new year

Jan 05

Jaguar Health inks second Mytesi royalties agreement for $6M

Dec 23

Does Jaguar Health (NASDAQ:JAGX) Have A Healthy Balance Sheet?

Dec 02
Does Jaguar Health (NASDAQ:JAGX) Have A Healthy Balance Sheet?

Jaguar Health's crofelemer development nears SPAC funding in Europe, shares +61%

Nov 30

Jaguar Health EPS misses by $0.10, misses on revenue

Nov 16

Jaguar Health receives positive Nasdaq listing determination

Oct 29

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: Insufficient data to determine if JAGX's dividends per share have been stable in the past.

Büyüyen Temettü: Insufficient data to determine if JAGX's dividend payments have been increasing.


Piyasaya Karşı Temettü Getirisi

Jaguar Health Piyasaya Karşı Temettü Getirisi
JAGX temettü verimi piyasa ile karşılaştırıldığında nasıldır?
SegmentTemettü Verimi
Şirket (JAGX)n/a
Pazarın Alt %25'i (US)1.5%
Pazarın En İyi %25'i (US)4.5%
Sektör Ortalaması (Pharmaceuticals)2.3%
Analist tahmini (JAGX) (3 yıla kadar)n/a

Önemli Temettü: Unable to evaluate JAGX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Yüksek Temettü: Unable to evaluate JAGX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: Insufficient data to calculate JAGX's payout ratio to determine if its dividend payments are covered by earnings.


Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: Unable to calculate sustainability of dividends as JAGX has not reported any payouts.


Güçlü temettü ödeyen şirketleri keşfedin